Developing therapies for patients
with serious, ultra-rare diseases
with serious, ultra-rare diseases
LEAD PROGRAM
We are working to obtain FDA approval for EDSIVO™
Treatment of vascular Ehlers-Danlos Syndrome
Acer is committed
to supporting patients
and families that need it most.
to supporting patients
and families that need it most.
PIPELINE
We are developing ACER-001
The first potential therapy for Maple Syrup Urine Disease
(MSUD); and the Urea Cycle Disorder (USD)
Acer is changing the path
to managing rare diseases
to managing rare diseases